FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026655889> ?p ?o ?g. }

• W3026655889 abstract "Background & Aim In Australia clinical trials of viral vector gene therapies or gene modified (GM) viruses are required to be licenced by the Office of the Gene Technology Regulator (OGTR). Institutional Biosafety Committees (IBCs) play a crucial role by reviewing applications before they go to the OGTR for decision. IBCs also advise on cell therapy trials that do not require a licence and on laboratory research. Their advice covers safety, compliance and governance to meet the objective of the Australian Gene Technology Act 2000, which ‘is to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with GMOs [Genetically Modified Organisms]’. Methods, Results & Conclusion Royal Prince Alfred Hospital (RPAH) IBC contributes to cell and gene therapy capacity building within Sydney Local Health District. Since 2008 it has advised on over 22 clinical trials; 14 of which required an OGTR licence. It has reviewed 6 licence applications and local risk management for 7 licences obtained via other IBCs. The number of trials advised on is increasing (5 in 2008-2015, 9 in 2016-2019 and 4 as at March 2020). They cover adeno-associated viral vectors for haemophilia, adenoviral vectors for mesothelioma, oncolytic GM human HSV-1 for melanoma and squamous cell carcinoma, oncolytic GM vaccinia virus vaccine strain for liver and kidney cancer, autologous cells transduced ex vivo with lentiviral vectors for beta-thalassemia (CD34+ cells) and adult diffuse large B-cell lymphoma (chimeric antigen receptor T cells targeting CD19) and allogeneic CRISPR Cas-9 engineered T-cells for B cell malignancies. The IBC conducts science-based risk assessments, facility inspections, assists organisations to prepare for cell and gene therapy clinical trials and contributes to policy and national reviews. It assists applicants and liaises with the OGTR. It has answered infection control queries, educated sponsors, developed a GMO-waste management training program with environmental services; ensured eye-wash, autoclave maintenance and spills management training are provided; assisted with corrective actions; and provided risk prevention advice. The members are scientists, researchers, health professionals, engineers and lay persons. The committee has processes for managing confidential information and dualities of interest and assesses new technologies, policies and regulations as they emerge." @default.
• W3026655889 created "2020-05-29" @default.
• W3026655889 creator A5006164525 @default.
• W3026655889 creator A5018086723 @default.
• W3026655889 creator A5020226654 @default.
• W3026655889 creator A5044097175 @default.
• W3026655889 creator A5088864473 @default.
• W3026655889 date "2020-05-01" @default.
• W3026655889 modified "2023-09-27" @default.
• W3026655889 title "How institutional biosafety committees contribute to safety, capacity and regulatory approvals in cell and gene therapy trials" @default.
• W3026655889 doi "https://doi.org/10.1016/j.jcyt.2020.04.078" @default.
• W3026655889 hasPublicationYear "2020" @default.
• W3026655889 type Work @default.
• W3026655889 sameAs 3026655889 @default.
• W3026655889 citedByCount "0" @default.
• W3026655889 crossrefType "journal-article" @default.
• W3026655889 hasAuthorship W3026655889A5006164525 @default.
• W3026655889 hasAuthorship W3026655889A5018086723 @default.
• W3026655889 hasAuthorship W3026655889A5020226654 @default.
• W3026655889 hasAuthorship W3026655889A5044097175 @default.
• W3026655889 hasAuthorship W3026655889A5088864473 @default.
• W3026655889 hasConcept C104317684 @default.
• W3026655889 hasConcept C111599444 @default.
• W3026655889 hasConcept C142724271 @default.
• W3026655889 hasConcept C159047783 @default.
• W3026655889 hasConcept C2522874641 @default.
• W3026655889 hasConcept C32470452 @default.
• W3026655889 hasConcept C40767141 @default.
• W3026655889 hasConcept C502942594 @default.
• W3026655889 hasConcept C52384281 @default.
• W3026655889 hasConcept C535046627 @default.
• W3026655889 hasConcept C55493867 @default.
• W3026655889 hasConcept C71924100 @default.
• W3026655889 hasConcept C82210918 @default.
• W3026655889 hasConcept C86803240 @default.
• W3026655889 hasConceptScore W3026655889C104317684 @default.
• W3026655889 hasConceptScore W3026655889C111599444 @default.
• W3026655889 hasConceptScore W3026655889C142724271 @default.
• W3026655889 hasConceptScore W3026655889C159047783 @default.
• W3026655889 hasConceptScore W3026655889C2522874641 @default.
• W3026655889 hasConceptScore W3026655889C32470452 @default.
• W3026655889 hasConceptScore W3026655889C40767141 @default.
• W3026655889 hasConceptScore W3026655889C502942594 @default.
• W3026655889 hasConceptScore W3026655889C52384281 @default.
• W3026655889 hasConceptScore W3026655889C535046627 @default.
• W3026655889 hasConceptScore W3026655889C55493867 @default.
• W3026655889 hasConceptScore W3026655889C71924100 @default.
• W3026655889 hasConceptScore W3026655889C82210918 @default.
• W3026655889 hasConceptScore W3026655889C86803240 @default.
• W3026655889 hasLocation W30266558891 @default.
• W3026655889 hasOpenAccess W3026655889 @default.
• W3026655889 hasPrimaryLocation W30266558891 @default.
• W3026655889 hasRelatedWork W10666957 @default.
• W3026655889 hasRelatedWork W11074086 @default.
• W3026655889 hasRelatedWork W1224117 @default.
• W3026655889 hasRelatedWork W15564899 @default.
• W3026655889 hasRelatedWork W2394888 @default.
• W3026655889 hasRelatedWork W2930566 @default.
• W3026655889 hasRelatedWork W4442719 @default.
• W3026655889 hasRelatedWork W746658 @default.
• W3026655889 hasRelatedWork W9856781 @default.
• W3026655889 hasRelatedWork W988812 @default.
• W3026655889 isParatext "false" @default.
• W3026655889 isRetracted "false" @default.
• W3026655889 magId "3026655889" @default.
• W3026655889 workType "article" @default.